Why Month 18 on Finasteride Feels Like Hitting a Wall — And the Clinical Strategies That Break Through It

There is a particular frustration that arrives quietly, somewhere between the 15th and 20th month of finasteride treatment. The early optimism — the shedding that stabilized, perhaps a few recovered follicles along the hairline — gives way to a plateau. The mirror looks the same week after week. For a significant portion of men, this is not imagination. It reflects a documented pattern in the clinical literature, and understanding it is the first step toward addressing it.

What the Clinical Data Actually Shows Around 18 Months

The pivotal trials that established finasteride's efficacy — including the landmark two-year studies published in the late 1990s — documented the drug's greatest measurable gains occurring within the first 12 months of treatment. Hair count improvements, as measured by standardized scalp photography and follicular density assessments, typically peaked somewhere between months 12 and 24, with the steepest gains concentrated in the first year.

By the 18-month mark, most men have experienced what researchers describe as a "treatment ceiling" for that particular regimen. This does not mean finasteride has stopped working in a meaningful sense. The drug continues to suppress dihydrotestosterone (DHT) — the androgen primarily responsible for follicular miniaturization in androgenetic alopecia — at a consistent rate. What changes is the follicular response to that suppression.

Simply put: the follicles most capable of responding to reduced DHT exposure have already responded. The ones that remain miniaturized may be further along in their degenerative cycle, less metabolically active, or operating within a microenvironment that finasteride alone cannot fully rehabilitate.

Is It a Perception Problem or a Biological One?

Before escalating treatment, it is worth separating two distinct phenomena that often get conflated at this stage.

The first is genuine plateau — measurable stabilization of hair density with no further net improvement. The second is what might be called perceptual fatigue: a patient who has grown accustomed to incremental gains and now interprets the absence of dramatic change as failure, even while the drug continues to prevent meaningful loss.

Clinicians frequently note that patients who discontinue finasteride at the 18-month mark — believing it has stopped working — often experience accelerated shedding within three to six months. This serves as an inadvertent confirmation that the drug remained pharmacologically active even when visible improvement had ceased. Maintenance, in hair loss medicine, is a legitimate and underappreciated form of success.

That said, for patients whose primary goal extends beyond stabilization to active regrowth, the distinction matters less. A plateau is a plateau, and there are evidence-informed approaches for addressing it.

Combination Therapy: The Most Clinically Supported Next Step

The most extensively studied approach to overcoming the finasteride plateau involves adding topical minoxidil to an existing finasteride regimen. The two agents work through entirely different mechanisms — finasteride targets hormonal pathways, while minoxidil acts as a vasodilator and potassium channel opener that prolongs the anagen (growth) phase of the hair cycle and may stimulate follicular activity independently of DHT.

Several studies, including a notable 2021 analysis published in the Journal of the American Academy of Dermatology, demonstrated that combination therapy produced superior hair density outcomes compared to either agent used alone. For men who have maximized what finasteride can do on its own, introducing topical minoxidil — typically at the 5% concentration formulated for men — represents a logical and well-tolerated escalation.

More recently, low-dose oral minoxidil (typically 2.5 mg to 5 mg daily) has emerged as an alternative for patients who find topical formulations inconvenient or who experience scalp irritation. While oral minoxidil carries its own side effect profile — including fluid retention and, less commonly, unwanted facial hair growth — it has shown meaningful efficacy in male androgenetic alopecia and is increasingly being prescribed by US dermatologists as an adjunct to finasteride.

Reassessing the Dose: Is 1 mg Still the Right Number?

Finasteride at 1 mg daily — the standard dosage approved by the FDA for male pattern baldness under the brand name Propecia — suppresses serum DHT by approximately 65 to 70 percent in most patients. For many men, this is sufficient. But individual pharmacokinetics vary, and some patients may metabolize the drug in ways that result in less consistent DHT suppression.

The 5 mg formulation, originally approved for benign prostatic hyperplasia, has been used off-label for hair loss in cases where the standard dose appears insufficient. Some clinicians argue that the incremental DHT suppression gained at higher doses — studies suggest 5 mg achieves roughly 70 to 75 percent suppression, a modest increase — may be meaningful for certain patients at a plateau, particularly those with more aggressive androgenetic alopecia patterns.

This is not a decision to make unilaterally. A conversation with a board-certified dermatologist or urologist who is familiar with hair loss pharmacology is essential before adjusting dosage, given the dose-dependent nature of finasteride's side effect profile.

Emerging Adjuncts: What the Research Pipeline Suggests

Beyond established combination therapies, several emerging interventions have attracted clinical attention as potential plateau-breakers.

Platelet-rich plasma (PRP) therapy involves injecting a concentration of the patient's own growth factors directly into the scalp. While the evidence base remains heterogeneous and large-scale randomized trials are still limited, several studies have shown statistically significant improvements in hair density when PRP is combined with pharmacological therapy. For men whose finasteride results have stalled, PRP represents a reasonable consideration — particularly at practices that specialize in hair restoration medicine.

Low-level laser therapy (LLLT), delivered via FDA-cleared devices such as laser combs or helmets, has demonstrated modest but real efficacy in stimulating follicular activity through photobiomodulation. The mechanism is distinct from both finasteride and minoxidil, making it a potentially complementary addition rather than a redundant one.

Topical finasteride with a penetration enhancer is an area of active development. Formulations designed to deliver finasteride directly to the scalp — minimizing systemic absorption while maintaining local DHT suppression — are available through compounding pharmacies and are increasingly being evaluated in clinical settings. This approach may offer a way to intensify local treatment without increasing systemic drug exposure.

What a Productive Conversation With Your Dermatologist Looks Like

If you are approaching or past the 18-month mark and feel your results have plateaued, the most productive step is a structured reassessment with a clinician rather than a unilateral change in your regimen.

Bring documentation if you have it — standardized photographs taken in consistent lighting, or records from any prior hair density assessments. Ask your dermatologist to evaluate whether what you are experiencing represents true plateau or continued maintenance, and discuss whether combination therapy, dosage adjustment, or procedural adjuncts are appropriate given your hair loss pattern, overall health, and treatment goals.

The 18-month plateau is not a dead end. It is, for many patients, a clinical inflection point — a moment when the initial phase of treatment has run its course and a more tailored, multimodal strategy becomes necessary. Understanding that distinction, and acting on it with accurate information, is what separates patients who give up on effective therapy from those who ultimately achieve meaningful, lasting results.